Abstract: A method for monitoring a sleep session of an individual comprises receiving data associated with a current sleep session of the individual; analyzing at least a portion of the received data to identify one or more sleep stages experienced by the individual during the current sleep session, the one or more sleep stages including a light sleep stage, a deep sleep stage, a typical rapid eye movement (REM) stage, an atypical REM stage, a wake stage, or any combination thereof; and generating a summary of the current sleep session, the summary including (i) a number of atypical REM sleep stages experienced by the individual during the sleep current sleep session, (ii) a time spent in atypical REM sleep stages during the current sleep session, or (iii) both (i) and (ii).

Abstract: A probiotic composition is provided comprising at least two isolated bacterial species or comprising a purified bacterial preparation comprising at least two bacterial species, wherein the at least two bacterial species are selected from the group consisting of Coprococcus catus, Eubacterium rectale, Alistipes putredinis, Barnesiella intestinihominis, Roseburia hominis, Dorea longicatena and Faecalibacterium prausnitzii. Also provided are specific isolated bacterial strains and use of the composition for treating frailty and/or inflammation related to aging in elderly subjects.

Abstract: The present disclosure relates to a method for determining a mouth leak status associated with a user of a respiratory device is disclosed. Airflow data associated with the user of the respiratory device is received. The respiratory device is configured to supply pressurized air to an airway of the user during a therapy session. The airflow data includes pressure data. The airflow data associated with the user is analyzed. Based at least in part on the analysis, the mouth leak status associated with the user is determined. The mouth leak status is indicative of whether or not air is leaking from a mouth of the user.

Abstract: The present invention relates to cPLA2e inducing agents and cPLA2e inducing agents for use as a medicament, particularly for use in the treatment of a cognitive disorder and/or disease associated with a cognitive disorder, for example dementia, and more specifically age-related dementia and/or Alzheimer's disease.

Abstract: The system comprises two frame structures (1) and (2) articulated with each other at their sides, the articulations (3) thereof incorporating bearings and connected in a simple manner by pins (14) and end washers (15), such that it incorporates lower supporting means that are stable at one end and rolling at the other end, whereby the elevation and lowering are performed by moving the frame structure (2) with a piston (10) that is driven by a motor (11), such that the piston (10) is articulated at its free end with a cross member (13) of the frame structure (2) and the motor (11) is articulated with the cross member (5?) of the frame structure (1). The frame structures end at the top in supports articulated with brackets in the form of forks (7) on which the bed base to be raised or lowered rests. The profiles used have a quadrangular cross-section, thereby providing a simple structure that is easily assembled and consequently inexpensive, usable with any bed base.

Abstract: The invention relates to a bracelet that is suitable for the transdermal delivery of various substances. The invention relates to, for example, a refillable, hollow bracelet that contains the substance and that is also provided with a filter that enables the product to be absorbed when in contact with the skin of the user. A mechanism enables the supply of said substance to be totally or partially interrupted. Additionally, the bracelet has a refilling device for refilling the bracelet when the substance runs out.

Abstract: The invention relates to a bracelet that is suitable for the transdermal delivery of various substances. The invention relates to, for example, a refillable, hollow bracelet that contains the substance and that is also provided with a filter that enables the product to be absorbed when in contact with the skin of the user. A mechanism enables the supply of said substance to be totally or partially interrupted. Additionally, the bracelet has a refilling device for refilling the bracelet when the substance runs out.

Abstract: Antitumor compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene group.

Abstract: A kitchenware magnifying device comprising of a kitchen utensil and a magnifying element disposed within the kitchen utensil. The kitchenware magnifying device is used to read labels or other written materials.

Abstract: Methods are provided for preparing a compound with a fused ring structure of formula (XIV) which comprises one or more reactions starting from a 21-cyano compound of formula (XVI) where typically; R1 is an amidomethylene group or an acyloxymethylene group; R5 and R8 are independently chosen from —H, —OH or —OCOCH2OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring; R14a and R14b are both —H ozone is —H and the other is —OH, —OCH3 or —OCH2CH3, or R14a and R14b together form a keto group; and R15 and R18 are independently chosen from —H or —OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring. In modified starting materials, the 21-cyano group can be replaced by other groups introduced using nucleophilic reagents.

Abstract: Compounds of the general formula (I) or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof are provided: wherein the substituent groups defined by R are each independently selected from the group consisting of H, SiR?3, SOR?, SO2X, C(?O)R?, C(?O)OR?, C(?O)NR?, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aryl, heteroaryl or aralkyl; the group R? is selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aminoalkyl, aryl, aralkyl and heterocyclic groups; and the group R? is selected from the group consisting of H, OH, OR?, OCOR?, SH, SR?, SOR?, SO2R?, NO2, NH2, NHR?, N(R?)2, NHCOR?, N(COR?)2, NHSO2R?, CN, halogen, C(?O)H, C(?O)R?, CO2H, CO2R?, CH2OR, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkylidene, substituted or unsubstituted alkynyl, substit

Abstract: Compounds of the general formula (I) or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof are provided: wherein the substituent groups defined by R are each independently selected from the group consisting of H, SiR?3, SOR?, SO2X, C(?O)R?, C(?O)OR?, C(?O)NR?, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aryl, heteroaryl or aralkyl; the group R? is selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aminoalkyl, aryl, aralkyl and heterocyclic groups; and the group R? is selected from the group consisting of H, OH, OR?, OCOR?, SH, SR?, SOR?, SO2R?, NO2, NH2, NHR?, N(R?)2, NHCOR?, N(COR?)2, NHSO2R?, CN, halogen, C(?O)H, C(?O)R?, CO2H, CO2R?, CH2OR, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkylidene, substituted or unsubstituted alkynyl, substit

Abstract: Processes are provided for preparing compounds with a fused ring structure of formula (XIV). Such products include ecteinascidins and have a spiroamine-1,4-bridge. The process involving forming a 1,4 bridge using a 1-labile, 10-hydroxy, 18-protected hydroxyl, di-6,8-en-5-one fused ring compound. After formation of the 1,4 brige, C-18 protection is removed before spiroamine introduction.

Abstract: Antitumor compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins.

Abstract: Compounds of the general formula (I) or pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof are provided: wherein the substituent groups defined by R are each independently selected from the group consisting of H, SiR?3, SOR?, SO2X, C(?O)R?, C(?O)OR?, C(?O)NR?, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aryl, heteroaryl or aralkyl; the group R? is selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aminoalkyl, aryl, aralkyl and heterocyclic groups; and the group R? is selected from the group consisting of H, OH, OR?, OCOR?, SH, SR?, SOR?, SO2R?, NO2, NH2, NHR?, N(R?)2, NHCOR?, N(COR?)2, NHSO2R?, CN, halogen, C(=O)H, C(=O)R?, CO2H, CO2R?, CH2OR, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkylidene, substituted or unsubstituted alkynyl, substitut

Abstract: Antitumor compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene group.

Abstract: Methods are provided for preparing a compound with a fused ring structure of formula (XIV) which comprises one or more reactions starting from a 21-cyano compound of formula (XVI) where typically; R1 is an amidomethylene group or an aryloxymethylene group; R5 and R8 are independently chosen from —H, —OH or —OCOCH2OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring; R14a and R14b are both —H ozone is —H and the other is —OH, —OCH3 or —OCH2CH3, or R14a and R14b together form a keto group; and R15 and R18 are independently chosen from —H or —OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring. In modified starting materials, the 21-cyano group can be replaced by other groups introduced using nucleophilic reagents.

Abstract: Antitumour compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene group.

Abstract: Methods are provided for preparing a compound with a fused ring structure of formula (XIV) which comprises one or more reactions starting from a 21-cyano compound of formula (XVI) where typically: R1 is an amidomethylene group or an acyloxymethylene group; R5 and R8 are independently chosen from —H, —OH or —OCOCH2OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring; R14a and R14b are both —H ozone is —H and the other is —OH, —OCH3 or —OCH2CH3, or R14a and R14b together form a keto group; and R15 and R18 are independently chosen from —H or —OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring. In modified starting materials, the 21-cyano group can be replaced by other groups introduced using nucleophilic reagents.

Abstract: Processes are provided for preparing compounds with a fused ring structure of formula (XIV). Such products include ecteinascidins and have a spiroamine-1,4-bridge. The process involving forming a 1,4 bridge using a 1-labile, 10-hydroxy, 18-protected hydroxyl, di-6,8-en-5-one fused ring compound. After formation of the 1,4 brige, C-18 protection is removed before spiroamine introduction.